Virtus ETF Advisers’s ANI Pharmaceuticals ANIP Stock Holding History

Virtus ETF Advisers’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.18M	Buy	14,294 +738	+5%	+$59.2K	0.45%	45
2026 Q1	$1.04M	Sell	13,556 -2,350	-15%	-$183K	0.48%	41
2025 Q4	$1.26M	Hold	15,906	–	–	0.59%	31
2025 Q3	$1.46M	Hold	15,906	–	–	0.8%	25
2025 Q2	$1.04M	Buy	15,906 +2,135	+16%	+$139K	0.63%	33
2025 Q1	$922K	Buy	+13,771	New	+$823K	0.6%	34

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus ETF Advisers's ANIP Position: Q2 2026 in Review

Virtus ETF Advisers increased its ANI Pharmaceuticals (ANIP) stake by 5.4% in Q2 2026, buying an estimated $59.2K and bringing the position to 14,294 shares worth $1.18M. The position accounts for 0.45% of the portfolio, ranked #45.

Virtus ETF Advisers first reported a position in ANIP in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.46M in Q3 2025. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Virtus ETF Advisers held 14,294 shares of ANI Pharmaceuticals worth $1.18M as of Q2 2026.
Virtus ETF Advisers bought 738 ANI Pharmaceuticals shares in Q2 2026, an estimated $59.2K.
ANI Pharmaceuticals made up 0.45% of Virtus ETF Advisers's portfolio in Q2 2026, its #45 holding.
Virtus ETF Advisers first reported a position in ANI Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Virtus ETF Advisers's ANI Pharmaceuticals position peaked at $1.46M in Q3 2025.
308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.